Generate Investment Management Ltd Makes New Investment in Stryker Corporation $SYK

Generate Investment Management Ltd bought a new stake in Stryker Corporation (NYSE:SYK) during the 4th quarter, HoldingsChannel reports. The fund bought 30,922 shares of the medical technology company’s stock, valued at approximately $10,868,000.

A number of other institutional investors and hedge funds have also made changes to their positions in SYK. Brighton Jones LLC lifted its position in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. purchased a new stake in Stryker in the 2nd quarter valued at approximately $205,000. Vinva Investment Management Ltd increased its position in Stryker by 15.3% during the 2nd quarter. Vinva Investment Management Ltd now owns 20,871 shares of the medical technology company’s stock worth $8,214,000 after purchasing an additional 2,773 shares during the period. Quadrant Capital Group LLC raised its stake in shares of Stryker by 12.0% during the 2nd quarter. Quadrant Capital Group LLC now owns 8,418 shares of the medical technology company’s stock worth $3,330,000 after buying an additional 904 shares in the last quarter. Finally, GM Advisory Group LLC raised its stake in shares of Stryker by 26.6% during the 2nd quarter. GM Advisory Group LLC now owns 1,019 shares of the medical technology company’s stock worth $403,000 after buying an additional 214 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

SYK opened at $327.49 on Friday. The stock has a market cap of $125.42 billion, a P/E ratio of 38.99, a P/E/G ratio of 1.94 and a beta of 0.85. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The stock’s 50 day simple moving average is $360.17 and its 200 day simple moving average is $363.90. Stryker Corporation has a 1-year low of $324.93 and a 1-year high of $404.87.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. The firm had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.Stryker’s revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the firm posted $4.01 earnings per share. As a group, equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s payout ratio is 41.90%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on SYK shares. Evercore set a $390.00 price target on Stryker in a research note on Monday, January 5th. Sanford C. Bernstein increased their price objective on Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. Robert W. Baird set a $437.00 target price on Stryker in a report on Friday, January 30th. Jefferies Financial Group restated a “buy” rating and set a $465.00 target price on shares of Stryker in a research report on Wednesday, March 4th. Finally, The Goldman Sachs Group set a $399.00 price target on shares of Stryker in a research note on Friday, January 9th. Fourteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $427.50.

Insider Activity

In related news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. The trade was a 9.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.90% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.